Focus: Stereotaxis is a public medical device company specializing in magnetic navigation systems for cardiac interventions, particularly catheter-based procedures in electrophysiology and coronary intervention. The company operates at modest scale with $27M in annual revenue, focused on niche high-precision surgical applications.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Stereotaxis to get notified when they start hiring — the background below is worth knowing for when they do.
Recently FDA-cleared (April 2026) next-generation cath lab system representing the company's flagship commercial asset and lead revenue driver.
Help build intelligence for Stereotaxis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Stereotaxis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Proprietary magnetic navigation platform enabling precision catheter control across multiple arrhythmia ablation and intervention procedures.
Stereotaxis bags FDA clearance for next-gen cath lab tech - Indian Pharma Post
Stereotaxis bags FDA clearance for next-gen cath lab tech Indian Pharma Post
Stereotaxis launches Synchrony system for cath labs - Medical Device Network
Stereotaxis launches Synchrony system for cath labs Medical Device Network
Stereotaxis’ Synchrony System Gets FDA OK & Launches - Medical Product Outsourcing
Stereotaxis’ Synchrony System Gets FDA OK & Launches Medical Product Outsourcing
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference The Manila Times
Stereotaxis Announces FDA Clearance and Launch of Synchrony System - GlobeNewswire
Stereotaxis Announces FDA Clearance and Launch of Synchrony System GlobeNewswire
8-K Filing: Stereotaxis, Inc. (STXS) (CIK 0001289340) — EX-99.1
EX-99.1
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo